NINA Medical develops noninvasive surgery technologies, extending the concept of next-generation medicine.
In noninvasive surgery, surgeon’s knife is replaced with a beam of focused energy, directed to the diseased tissue (e.g. a tumor), providing local and selective therapy.
The technology eliminates the need to cut healthy tissue in order to get access to the diseased tissue, where treatment is required. Since tissue-disruption does not occur, bleeding is rare in noninvasive surgery; therefore, pain and overall trauma for the patient are greatly reduced, as well as the burden on health systems and infrastructures.
For us, next generation medicine is about focused therapy – “Treat. Don’t injure.”
NINA Medical is keen to introduce innovative and affordable solutions that will increase the accessibility of high-quality medicine to the public. As a result, more people will get to receive the medical care they need.
Live ultrasound imaging of the HIFU beam


High intensity focused ultrasound (HIFU) is the best choice for the energy in noninvasive surgery; ultrasound can travel through soft tissue, and it can be focused into a small region in the body. The intensity at the focal point can be made very high, sufficient to ‘burn’ a voxel of tissue. The result is a modality which is capable of remotely induce a controlled damage to tissue for medical purposes, e.g. tumor ablation.
NINA Medical‘s proprietary technology provides live imaging of the HIFU beam profile, displaying the actual position and shape of the focal point in real-time.
This is accomplished by the implementation of novel techniques in diagnostic ultrasound, with the HIFU running in “navigation mode” at low and safe intensity.
Therefore, a closed-loop image-guided HIFU is provided. The technology is being implemented in an affordable medical device for noninvasive surgery.


Uterine fibroids are common benign smooth muscle tumors of the uterus. Most women will develop one or more uterine fibroids during their reproductive lifespan. In the United States, an estimated 26 million women between the ages of 15 and 50 have uterine fibroids. More than 15 million of them will experience associated symptoms or health concerns.


With 600,000 hysterectomy procedures in the US, about 50% of them related to symptomatic leiomyoma (uterine fibroids), the direct annual cost to the American market is estimated in $2.1B

(Cardozo et. al., AJOG 2012)


Most women preferred non-invasive options for treatment… many women expressed a clear desire to keep their uterus
(Borah et. al., AJOG 2013)



Shmuel Ben-Ezra, MSc, Founder and CEO

Yoni Hertzberg, PhD, MBA, Founder and CTO

Zohar Gendler, MSc, Chairman of the board